Literature DB >> 21849225

Kidney tubular toxicity of maintenance pemetrexed therapy.

Ilya G Glezerman1, M Catherine Pietanza, Vincent Miller, Surya V Seshan.   

Abstract

Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer. Major side effects include myelosuppression and neutropenia. Three patients developed kidney disease while being treated with maintenance pemetrexed. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case. Kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy in all cases.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21849225     DOI： 10.1053/j.ajkd.2011.04.030

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  15 in total

1.  Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

Authors:  Jorg Dietrich; Laura Versmee; Jan Drappatz; April F Eichler; Lakshmi Nayak; Andrew Norden; Eric Wong; Michelle R Pisapia; SooAe S Jones; Amanda B Gordon; Bruce A Chabner; Fred Hochberg; Tracy T Batchelor
Journal:  Oncologist       Date:  2020-07-01

2.  Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.

Authors:  Giuseppe Rombolà; Franco Vaira; Matteo Trezzi; Nadia Chiappini; Valeria Falqui; Francesco Londrino
Journal:  J Nephrol       Date:  2014-07-02       Impact factor: 3.902

3.  Pemetrexed-Induced Nephrogenic Diabetes Insipidus.

Authors:  Enrica Fung; Shuchi Anand; Vivek Bhalla
Journal:  Am J Kidney Dis       Date:  2016-05-28       Impact factor: 8.860

4.  Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.

Authors:  Anika L Dzierlenga; John D Clarke; David M Klein; Tarun Anumol; Shane A Snyder; HongYu Li; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2016-05-27       Impact factor: 4.030

5.  Nephrotoxicity in a Patient Treated with Pemetrexed.

Authors:  Y Zajjari; M Azizi; Y Sbitti; D El Kabbaj
Journal:  Indian J Nephrol       Date:  2017 May-Jun

6.  Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.

Authors:  Shruti Gupta; Ian A Strohbehn; Qiyu Wang; Paul E Hanna; Rituvanthikaa Seethapathy; Jason M Prosek; Sandra M Herrmann; Ala Abudayyeh; A Bilal Malik; Sebastian Loew; Christopher A Carlos; Wei-Ting Chang; Pazit Beckerman; Zain Mithani; Chintan V Shah; Amanda D Renaghan; Sophie de Seigneux; Luca Campedel; Abhijat Kitchlu; Daniel Sanghoon Shin; Gaia Coppock; Nuttha Lumlertgul; Pablo Garcia; David I Ortiz-Melo; Arash Rashidi; Ben Sprangers; Vikram Aggarwal; Karolina Benesova; Kenar D Jhaveri; Frank B Cortazar; Astrid Weins; Yiqin Zuo; Meghan J Mooradian; Kerry L Reynolds; David E Leaf; Meghan E Sise
Journal:  Kidney Int       Date:  2022-08-11       Impact factor: 18.998

7.  EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.

Authors:  Liang Yang; Hanghang Fang; Jingjing Jiang; Yongjie Sha; Zhiyuan Zhong; Fenghua Meng
Journal:  Drug Deliv Transl Res       Date:  2021-11-20       Impact factor: 5.671

8.  A cross-sectional study of chemotherapy-related AKI.

Authors:  Xin Kang; Xizi Zheng; Damin Xu; Tao Su; Ying Zhou; Jing Ji; Qi Yu; Yimin Cui; Li Yang
Journal:  Eur J Clin Pharmacol       Date:  2021-05-15       Impact factor: 2.953

Review 9.  Drug-induced impairment of renal function.

Authors:  George Sunny Pazhayattil; Anushree C Shirali
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-12-12

Review 10.  Role of Oxidative Stress in Drug-Induced Kidney Injury.

Authors:  Keiko Hosohata
Journal:  Int J Mol Sci       Date:  2016-11-01       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.